证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|----------------------|-------------------------------------------------------------------------------|-----------------| | | | | 编号： 2016-002 | | | ■ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系 | □ | 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | | □ 其他 | | | | | | 泓盛资产张云鹏、信诚基金杨强、华富基金傅晟、海通证 | | | 参与单位名称 | | 券刘海荣、朱雀投资张皓、国泰君安陈宏亮、国信证券江 | | | 及人员姓名 | | 维娜、徐衍鹏、宏道投资杨洁、圆信永丰基金范妍、银河 基金余科苗、融通基金曹珊珊 | | | 时间 | 2016 年 3 月 | 21 日 | | ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------|------------------------------| | | | 编号： 2016-005 | | | ■ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 兴业证券夏飞虹、李佳黎，兴业全球基金张倍铭、赵梓 | | | 及人员姓名 | 焜、杨世进 | | | 时间 | 2016 年 11 月 1 日 | | | 地点 | 浙江省台州市椒江区外沙支路 100 | 号公司会议室 | | | 董事会秘书：许华青 | | | 上市公司接待 人员姓名 | 证券事务代表：蒋如东 | | | | 1 、公司 1.5 万吨 KN-R | 项目进展情况？将来新产 ...

证券代码：002099 证券简称：海翔药业 | --- | --- | --- | --- | --- | |--------------|----------------------|-------|----------------------------------------------------|-----------------| | | | | | 编号： 2017-003 | | | □ | | 特定对象调研 □分析师会议 | | | | □ | | 媒体采访 □业绩说明会 | | | 投资者关系 | □ | | 新闻发布会 □路演活动 | | | 活动类别 | □ | | 现场参观 ■投资者接待日活动 | | | | □其他 | | | | | 参与单位名称 | | | 杭商资产许俊杰，万林国际孙凯，富国基金孙彬、信诚基 | | | 及人员姓名 | | | 金韩益平，兴全基金徐武剑，金斧子王小进 | | | 时间 | 2017 年 5 月 | 日 | 11 | | | 地点 | | 100 | 浙江省台州市椒江区外沙支路 号公司会议室 | | | | 董事长：孙杨 | | | | | | 监 ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|----------------------------------|-----------------|-----------------------------------------------------------------------------------------------------| | | | 编号： 2017-002 | | | | ■ 特定对象调研 □分析师会议 | | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | | 活动类别 | □ 现场参观 | | | | | | | | | | □ 其他 | | | | 参与单位名称 | | | 弘晖资本严竞然，平安资管黄文锋，国投瑞银潘天奇，神 农投资殷南秋，理成资产张伟，中泰证券池陈森、祝嘉 | | 及人员姓名 | 琦，华泰资管梅力扬，通用投资程偲 | | | | 时间 | 2017 年 5 月 ...

Group 1: Company Overview - The company has undergone restructuring and is now a dual-driven listed company in pharmaceuticals and dyes, with both sectors contributing similarly to revenue, although dyes have a larger profit share [3] - The dye project with a capacity of 30,000 tons has received environmental approval and construction is underway [3] - The company aims for both organic growth and external mergers and acquisitions to achieve rapid growth [3] Group 2: Investment Strategy - Recent external investments have been small and non-controlling, focusing on internal management and resource integration post-restructuring [3] - The company invested in Rixing Biotechnology, a major producer of anthraquinone intermediates, aligning with its industry background [3] - The company is cautious about external investments, seeking to leverage professional institutions for suitable targets and considering integration into the listed company structure only after thorough evaluation [4] Group 3: Market Position and Pricing - The company produces active dyes, distinguishing itself from competitors who only handle specific segments, and holds significant pricing power in the market [4] - It is the largest global producer of the active dye KN-R, which is expected to maintain stable pricing in the short term [4]

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |--------------|--------------------------------------------------------------------------------------------|--------------------------------------| | | | | | | ■ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ 其他 | | | | 2017 年 2 月 9 | 日来访人员：香溢融通陈晔、施力楠，侏 | | | 罗纪资本程金龙、九泰基金欧阳之光、财通资管肖令君， | | | | 晓沫投资邓浩龙，中信建投郑勇，创证券陈凯茜，泓盛资 | | | | | | | 参与单位名称 | 本张云鹏，西证创新王家晨，长信基金朱垚，杭州热联集 | | | 及人员姓名 | 团章昊秋 ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|-------------------------|-------|----------------------------------------------|-----------------| | | | | | 编号： 2017-004 | | | | | | | | | □ | | 特定对象调研 □分析师会议 | | | 投资者关系 | □ | | 媒体采访 □业绩说明会 | | | 活动类别 | □ 新闻发布会 □路演活动 | | | | | | □ | | 现场参观 ■投资者接待日活动 | | | | □其他 | | | | | 参与单位名称 | | | 广发证券刘文祥、东吴证券金南、睿郡资产王子尧 | | | 及人员姓名 | | | | | | 时间 | 2017 年 9 月 18 | 日 | | | | | | 71 | 浙江省台州市椒江区岩头工业区海虹路 | 号台州前进会 | | 地点 | 议室 | | | ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|------------------------|-----------------|------------------------------------------------|----------| | | | | 编号： | 2017-005 | | | ■ | | 特定对象调研 □分析师会议 | | | | □ | | 媒体采访 □业绩说明会 | | | 投资者关系 | □ | | 新闻发布会 □路演活动 | | | 活动类别 | □ | | 现场参观 □投资者接待日活动 | | | | □其他 | | | | | 参与单位名称 | 个人投资者王洪阳 | | | | | 及人员姓名 | | | | | | 时间 | 2017 年 12 月 | 日 | 4 | | | 地点 | 上海市浦东新区世纪大道 | 88 号金茂大厦 | | | | 上市公司接待 | 董事会秘书：许华青 | | | | | 人员姓名 | | | ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-------------------------|------------------------------------|-------------------| | | | | 编号： 2019-006 | | | ■ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | | 活动类别 | □ | 现场参观 □投资者接待日活动 | | | | □其他 | | | | 参与单位名称 | 西南证券黄景文、黄宇 | | | | 及人员姓名 | | | | | 时间 | 2019 年 9 月 16 | 日 | | | | | 浙江省台州市椒江区岩头工业区海虹路 | 71 号台州前进会 | | 地点 | 议室 | | | | 上市公司接待 | 董事会秘书：许华青 | | | | 人员姓名 | 证券事务代表：蒋如东 | | | | --- | --- ...

Group 1: Company Overview and Financial Performance - Zhejiang Haixiang Pharmaceutical Co., Ltd. reported that its subsidiary, Ouhua Chemical, contributed 8.88% to the company's total revenue in 2018 and 2.44% to the net profit [4] - The company is focusing on expanding its product line along the anthraquinone industrial chain, with a new project for 15,500 tons of reactive dyes expected to start production in September 2019 [4][6] Group 2: Market and Product Insights - The company does not use or produce aniline, a key intermediate for disperse dyes, and its dye products are primarily reactive dyes for natural fabrics [2] - The domestic dye industry is experiencing price increases due to supply constraints, with the company planning to adjust its pricing based on market changes and raw material costs [2][3] - The company is a major global producer of KN-R, with a complete industrial chain that allows for self-sufficiency in intermediates [3] Group 3: Safety and Environmental Measures - Following the March 21 safety incident, the company has conducted thorough safety inspections and has not experienced any damage to its facilities [4] - The company invests heavily in safety and environmental measures, including employee training and the implementation of automated and closed-loop systems to enhance safety [5][6] Group 4: Future Growth and Challenges - The company anticipates significant growth in its clindamycin series products, driven by demand from international high-end markets [5] - The company faces challenges in the current environmental and safety landscape, but it is committed to maintaining its core competencies in these areas for sustainable development [6]